SOURCE: Implant Sciences Corporation

Implant Sciences Corporation

November 12, 2012 07:00 ET

Implant Sciences Wins Defense Contract in Middle East

WILMINGTON, MA--(Marketwire - Nov 12, 2012) - Continuing its penetration into the Middle East market, Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it has sold four Quantum Sniffer™ QS-H150 handheld explosives trace detection systems to the military branch of a Middle Eastern nation.

The sale was made by Bahrain-based Building Defence Systems (BDS), Implant Sciences' international distributor. BDS provides intelligent telecommunications systems and security solutions for critical corporate and government infrastructure. BDS has sold technology used by national governments, oil companies, and blue chip organizations in Bahrain, Qatar, the UAE, Iraq, Jordan, Saudi Arabia, Europe and the U.S.

"The QS-H150's portability and ability to cope with challenging Middle East environmental conditions were key factors in this sale. Fast, accurate, and easy to use, our Quantum Sniffers have gained a reputation for excellence across the world. We believe these factors will support continued growth in the Middle East," stated Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones.

About the Quantum Sniffer™ QS-H150 Handheld Explosives Trace Detector

The Quantum Sniffer QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 desktop explosives and drugs trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:

    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    CEO
    978-752-1700
    Email Contact

    or

    Investor Contact:
    Laurel Moody
    646-810-0608
    Email Contact